- Home
- AHG vs KALV Comparison
AHG vs KALV Comparison
Compare AHG & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHG
- KALV
- Stock Information
- Founded
- AHG 2013
- KALV N/A
- Country
- AHG China
- KALV United States
- Employees
- AHG N/A
- KALV N/A
- Industry
- AHG Business Services
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- AHG Consumer Discretionary
- KALV Health Care
- Exchange
- AHG Nasdaq
- KALV Nasdaq
- Market Cap
- AHG 765.9M
- KALV 725.3M
- IPO Year
- AHG N/A
- KALV N/A
- Fundamental
- Price
- AHG $1.70
- KALV $13.63
- Analyst Decision
- AHG
- KALV Strong Buy
- Analyst Count
- AHG 0
- KALV 9
- Target Price
- AHG N/A
- KALV $26.29
- AVG Volume (30 Days)
- AHG 94.8K
- KALV 1.9M
- Earning Date
- AHG 08-12-2025
- KALV 07-10-2025
- Dividend Yield
- AHG N/A
- KALV N/A
- EPS Growth
- AHG N/A
- KALV N/A
- EPS
- AHG N/A
- KALV N/A
- Revenue
- AHG $8,454,946.00
- KALV N/A
- Revenue This Year
- AHG N/A
- KALV N/A
- Revenue Next Year
- AHG N/A
- KALV $347.19
- P/E Ratio
- AHG N/A
- KALV N/A
- Revenue Growth
- AHG 281.19
- KALV N/A
- 52 Week Low
- AHG $0.74
- KALV $7.30
- 52 Week High
- AHG $2.35
- KALV $16.32
- Technical
- Relative Strength Index (RSI)
- AHG 51.61
- KALV 45.11
- Support Level
- AHG $1.56
- KALV $13.26
- Resistance Level
- AHG $2.10
- KALV $14.35
- Average True Range (ATR)
- AHG 0.25
- KALV 0.76
- MACD
- AHG -0.02
- KALV -0.29
- Stochastic Oscillator
- AHG 27.75
- KALV 12.46
About AHG Akso Health Group ADS
Akso Health Group formerly Xiaobai Maimai Inc is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.